Stocks and Investing
Stocks and Investing
Tue, November 8, 2016
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 01:46 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 12:45 AM ] - United States, WOPRAI
[ 12:45 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Salim Syed Initiated (BIIB) at Hold and Held Target at $290 on, Nov 8th, 2016
Salim Syed of Mizuho, Initiated "Biogen Inc." (BIIB) at Hold and Held Target at $290 on, Nov 8th, 2016.
Salim has made no other calls on BIIB in the last 4 months.
There are 4 other peers that have a rating on BIIB. Out of the 4 peers that are also analyzing BIIB, 1 agrees with Salim's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Eun Yang of "Jefferies" Maintained at Hold with Decreased Target to $316 on, Wednesday, October 5th, 2016
These are the ratings of the 3 analyists that currently disagree with Salim
- Christopher Raymond of "Piper Sandler" Upgraded from Hold to Buy on, Monday, November 7th, 2016
- Geoffrey Porges of "Leerink Swann" Upgraded from Hold to Buy on, Monday, November 7th, 2016
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $368 on, Wednesday, August 17th, 2016
Contributing Sources